IDEXX Q1 Beats and Raises as Diagnostics Decouple from Vet Visits

Q1 2026 revenue at IDEXX Laboratories (NASDAQ: IDXX) grew 14% reported and 11% organic, and the company raised full-year guidance — even as US same-store clinical visits at customer practices fell about 1% in the quarter. Diagnostics utilization is rising while traffic falls. It's the cleanest evidence yet that what happens inside the vet visit is shifting faster than the vet visit itself.

IDEXX Q1 revenue up 14%, full-year guide raised

Q1 2026 revenue at IDEXX was $1.141 billion, up 14% reported and 11% organic. Companion Animal Group revenue grew 15% reported and 12% organic. EPS came in at $3.47 per diluted share, up 17% reported and 15% comparable.

CAG Diagnostics recurring revenue grew more than 11% organic. US recurring was up about 11%; international up about 12%. The print landed against a US headwind: same-store clinical visits at customer practices fell about 1% in the quarter.

Instrument revenue grew 28% organic. The company placed 4,650 premium analyzers in the quarter, including 1,100 InViewDX units, expanded its InViewDX FNA rollout, grew Cancer Dx adoption to 7,500 practices, and posted record imaging and cloud-native software installations.

Full-year 2026 guidance was raised to revenue of $4.675 billion to $4.76 billion (8.6% to 10.6% reported, 7.7% to 9.7% organic). Organic CAG Diagnostics recurring revenue is now guided to 8.7% to 10.7%. EPS guidance was raised to $14.45 to $14.90.

The beat-and-raise lands the same week Zoetis printed flat organic and called out a 11% drop in US companion animal sales.

Why diagnostics is decoupling from the vet visit

The contrast with Zoetis is the story. Same customer (the US vet practice). Two very different pictures of what's happening inside.

1. Tests-per-visit is rising faster than visit count. US same-store visits down 1%, combined with double-digit diagnostic recurring growth, is a clean utilization story. Practices are running more tests per patient with newer instruments. For anyone building vet-software, RCM, or vet-side AI, the volume metric to model is "tests per visit," not "visits."

2. Instrument placements compound for years. A 28% organic instrument quarter signals practices are signing into multi-year reagent commitments at a confident pace. Once an InViewDX or Catalyst One is on the bench, the recurring revenue compounds. The razor-and-blades model is inflecting on a fleet that took a decade to install.

3. Cancer Dx at 7,500 practices is going mainstream. Pair this with VolitionRx submitting its Nu.Q feline cancer test manuscript the same week, and pet oncology screening has moved from specialist procedure to wellness-visit add-on. Operators in pet insurance, telemedicine, and oncology referral networks should model materially higher screening attach rates within 24 months.

4. The Zoetis-IDEXX divergence reframes the bear case for vet services. If the bear was "fewer pets, fewer visits, less revenue per practice," IDEXX shows revenue per visit can offset softer visit count at the diagnostics layer. The Rx side, per Zoetis, has no such cushion. Vet group economics are now diagnostics-driven, not Rx-driven.

5. The raised guide is forward visibility, not Q1 strength. Beat-and-raise mid-Q1 means management has line-of-sight on Q2 reagent and instrument pull. For consolidators, distributors, and DTC pet brands modeling vet-channel demand, that visibility itself is the data point.

What Q2 will reveal about practice utilization

Same-store visits trend: Whether the -1% holds, deepens, or reverses. The cleanest read on US pet end-market demand we have, reported quarterly.

Cancer Dx practice count: 7,500 today on a base of roughly 30,000 small-animal practices in the US. Adoption is still early. Watch the cadence of new practice adds.

InViewDX FNA traction: Pulling in-clinic cytology in-house redefines workflow for both general practice and oncology referral. Watch the share shift from outside reference labs.

Reagent attach on the new fleet: New instruments only matter if reagent volume follows. Q2 should clarify whether the 4,650 placements drive recurring guide higher again.

CAG comp resilience: 12% organic CAG was against a softer prior-year base. Holding mid-double-digits on a tougher Q2 comp is the bull case for the segment.

Source: IDEXX Q1 2026 release via Business Wire